Evotec stock gets new Goldman ownership signal after threshold change
Published on 11/12/2026 at 17:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGoldman Position Changes The Picture
- Goldman Sachs reported a lower combined position in Evotec instruments after a threshold event on November 5.
- The filing includes shares, recall rights, a right of use, a convertible bond, a call warrant and a cash-settled swap.
- Evotec's partnership-led drug discovery model remains central to the investment case.
Goldman Sachs reported a new position disclosure for Evotec on Thursday, November 12, 2026, after a threshold event on November 5. The filing adds a fresh ownership signal to the recent focus on Evotec's profitability recovery, cost program and partnership pipeline.
The EQS News announcement said Goldman Sachs held a combined 8.60 percent position, down from 12.05 percent in the previous notification. The new total comprised 0.32 percent in voting rights attached to shares and 8.28 percent through instruments.
What The Filing Contains
The instrument position included 7.16 percent under recall rights, right-of-use arrangements and a convertible bond, plus 1.12 percent through a cash-settled call warrant and swap. Goldman Sachs reported 569,545 Evotec shares indirectly, while the total position represented 177,948,497 voting rights under the filing basis.
The announcement date and the threshold date are different: the filing was released at 16:23 CET on November 12, while the threshold was crossed on November 5. The disclosure does not itself establish why the position changed or how the market will respond.
Share Price And Investor Focus
Evotec stock traded at 3.13 euros on Lang & Schwarz at 17:31 CET on Thursday, November 12, 2026. That was 3.10 percent below the 3.23-euro Lang & Schwarz indication at 07:58 CET in the latest pre-market report; this comparison is between the two Lang & Schwarz quotes, not a Xetra session comparison.
Evotec SE at a glance
- Company: Evotec SE
- ISIN: DE0005664809
- Lang & Schwarz quote: 3.13 euros on November 12, 2026 at 17:31 CET
- Ownership disclosure: Goldman Sachs combined position of 8.60 percent
- Threshold date: November 5, 2026
- Filing release: November 12, 2026 at 16:23 CET
European biotech shares remain sensitive to financing conditions, clinical progress and partnership news. Investors can follow the Euro Stoxx 50 for the broader regional market backdrop.
For more company-specific coverage, see More news and analyses on Evotec stock.
